Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Psoriasis therapy with biologicals].

U Mrowietz1

  • 1Abt. Dermatologie, Venerologie und Allergologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel. umrowietz@dermatology.uni-kiel.de

Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete
|March 14, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[On the occasion of Professor Enno Christophers's 90th birthday].

Dermatologie (Heidelberg, Germany)·2026
Same author

Depression, a major comorbidity of psoriatic disease, is caused by metabolic inflammation.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Measuring well-being in psoriasis: psychometric properties of the WHO-5 questionnaire.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

EczemaPartner - adapting a questionnaire to assess the impact of atopic dermatitis on partners of patients.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same journal

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Viral infections of the skin].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Viral exanthems in children].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Erratum to: Digital health applications and data protection].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Virus-induced exanthems in returning travellers].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Venous ulcus cruris-Surgical treatment].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
See all related articles

Biologicals, including monoclonal antibodies and recombinant proteins, offer new psoriasis treatments by targeting disease pathways. These biotechnologically produced compounds are revolutionizing therapy by modulating immune responses and blocking inflammatory cell activity.

Area of Science:

  • Biotechnology and Immunology
  • Dermatology
  • Pharmacology

Background:

  • Psoriasis pathogenesis involves complex cell and mediator systems.
  • Current understanding of psoriasis focuses on targeting key immune components.
  • Biotechnology enables the development of novel therapeutic agents.

Purpose of the Study:

  • To review current knowledge on biological therapies for psoriasis.
  • To highlight the role of biotechnology in developing new psoriasis treatments.
  • To discuss various mechanisms of action for biologicals in psoriasis.

Main Methods:

  • Review of scientific literature on biologicals and psoriasis therapy.
  • Analysis of pathogenetic studies to identify therapeutic targets.
  • Categorization of biological agents based on their mechanism of action.

Related Experiment Videos

Main Results:

  • Biologicals, such as monoclonal antibodies and fusion proteins, are effective in treating psoriasis.
  • Targeting tumor-necrosis-factor alpha and cytokine receptors are key strategies.
  • Interference with T cell activation and blockade of adhesion molecules are emerging therapeutic approaches.

Conclusions:

  • Biologicals represent a significant advancement in psoriasis treatment.
  • Targeted therapies based on immunological pathways offer improved outcomes.
  • Continued research in biotechnology promises further innovations in psoriasis management.